UMIN ID: C000000414
Registered date:02/05/2006
Clinical study of adjuvant immuno-cell therapy for pancreatic cancer curatively resectable.
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Pancreatic cancer |
| Date of first enrollment | 2006/03/01 |
| Target sample size | 10 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | Immuno-cell therapy(CD3-LAK) is done on day0, day14, day28, day42, day56, day70, day84, day98, day112. Gemcitabine is administered on day49, day63, day77, day91, day105, day119, day133, day147, day161, day175, day189, day203. |
Outcome(s)
| Primary Outcome | Relapse-free survival rate of relapse |
|---|---|
| Secondary Outcome | Safety Overall survival QOL(KPS) Immunological parameter |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | 75years-old |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Patients who have: uncontrolled infections, active autoimmune diseases, and serious cardiac disease; who have received continuous systemic steroids; who are pregnant, to be pregnant, or nursing mothers, and whom principle investigator or co-investigator judged to be inappropriate to participate in this study. |
Related Information
| Primary Sponsor | Yokohama City University Hospital |
|---|---|
| Secondary Sponsor | Shinyokohama medical clinic |
| Source(s) of Monetary Support | Medinet Co.,Ltd. |
| Secondary ID(s) |
Contact
| public contact | |
| Name | |
| Address | 3-9 Fukuura,Kanazawa-ku,Yokohama,Japan Japan |
| Telephone | 045-787-2650 |
| Affiliation | Yokohama City University Hospital Department of Gastroenterological Surgery |
| scientific contact | |
| Name | Yasushi Ichikawa |
| Address | 3-9 Fukuura,Kanazawa-ku,Yokohama,Japan Japan |
| Telephone | 045-787-2650 |
| Affiliation | Yokohama City University Hospital Department of Gastroenterological Surgery |